Provider of an iPSC technology platform for drug discovery designed to produce induced pluripotent stem cells. The company's technology platform is at the forefront of the production and differentiation of human induced pluripotent stem cells (hiPSC), which is quickly advancing the field of pre-clinical disease modelling, and drug safety evaluation, enabling researchers to research and test new drugs and screen potential drug molecules for efficacy and toxicity.